Menu

Bristol-Myers Squibb

Bristol-Myers Squibb Statement on Top-Line Results from CheckMate – 026

, , , ,

August 5, 2016 – While the news regarding CheckMate – 026 is disappointing, Bristol-Myers Squibb is proud of all that the company has and aims to accomplish with Opdivo. We are indeed transforming cancer care, and remain committed to bringing the benefit of our medicines to the greatest number of patients across multiple cancers. We […]

GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets

, , , , ,

Two transactions further strengthen HIV pipeline and outlook 18 December 2015, London – GlaxoSmithKline plc (LSE: GSK) today announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets. Under the […]